[Pathophysiological role of tissue renin-angiotensin-aldosterone system (RAAS) in human atherosclerosis]

Kensuke Fukui1, Hiroyuki Yamada, Hiroaki Matsubara

  • 1Department of Cardiovascular Medicine, Kyoto Prefectural University of Medicine.

Insights

The renin-angiotensin-aldosterone system (RAAS) is crucial in atherosclerosis. Blocking RAAS offers cardiovascular benefits beyond blood pressure reduction, but its plaque-stabilizing mechanisms require further study.

Area of Science:

  • Cardiovascular Research
  • Endocrinology
  • Pathophysiology

Context:

  • The renin-angiotensin-aldosterone system (RAAS) is implicated in atherosclerosis development.
  • RAAS blockade shows cardiovascular benefits, including improved endothelial function and reduced mortality/morbidity.
  • Mechanisms for plaque stabilization and rupture inhibition by RAAS blockade are not fully understood.

Purpose:

  • To summarize tissue RAAS expression in human atherosclerotic lesions.
  • To assess the therapeutic relevance of RAAS in preventing atherosclerotic cardiovascular diseases.

Summary:

  • RAAS plays a significant role in atherosclerosis pathogenesis.
  • RAAS blockade provides cardiovascular protection independent of blood pressure effects.
  • Further research is needed to elucidate RAAS's role in plaque stabilization and acute coronary syndrome prevention.

Impact:

  • Understanding tissue RAAS expression can guide therapeutic strategies for atherosclerotic cardiovascular diseases.
  • Elucidating RAAS mechanisms may lead to novel treatments for vulnerable plaque and acute coronary syndrome.
  • This review highlights the therapeutic potential of targeting RAAS in cardiovascular disease prevention.

Related Concept Videos

Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...